FTC Says Likely Pay-For-Delay Deals Remain Few
The number
of potentially anti-competitive patent infringement litigation settlements
between brand drugmakers and their would-be generic rivals continued to trend
downward through the end of 2017, according to the Federal Trade Commission's
latest staff report.
Report
attached |
No comments:
Post a Comment